Led · Series A · Oct 2022

Globish operates an online platform offering one-on-one foreign language lessons in English and Chinese for students and professionals. The company runs lessons in Thailand and Vietnam and delivers more than 300,000 lessons annually. It employs 400 teachers and plans to hire an additional 600 instructors. Globish expects to have taught 500,000 lessons by the end of the year and projects $35 million in sales by 2025. The business says the majority of its clients are workers seeking career advancement, with the remainder being students. It intends to use the new funding to expand into new markets including Bangladesh and Pakistan.

Led · Equity · Feb 2022

Qventus provides AI-based software that automates care operations across operating room and inpatient settings. The platform integrates with EHRs and leverages Generative AI, machine learning, and behavioral science to predict operational bottlenecks, recommend remedies, and automate processes. Its core offerings include Surgical Growth/Perioperative and Inpatient Capacity solutions that help care teams optimize patient flow and reduce cognitive load. In the last year its Inpatient Solution eliminated over 36,000 excess days for health system partners, saving them millions, and its Perioperative Solution generated $95M in annualized contribution margin in 2024 through Qventus-enabled cases. Led by CEO Mudit Garg and founded in 2012, the company intends to expand its AI Operational Assistants into new care settings beyond its current solutions. It plans to use recent funding to accelerate development and commercialization of those solutions. Qventus offers an AI-based SaaS platform purpose-built to automate care operations, integrating with EHRs and using AI, machine learning, and behavioral science. Its solutions target inpatient, perioperative, emergency department, and command center functions to improve operational workflows. The company partners with leading health systems, including Boston Medical Center, HonorHealth, M Health Fairview, Mercy, and Saint Luke’s Health System. Qventus is led by co-founder and CEO Mudit Garg and continues to expand its footprint across U.S. hospitals. Financially, the company recently attracted outside funding, including a $3M investment tied to prior growth financing announced in February 2022. Qventus provides AI-based software for care operations automation that integrates with EHRs. The platform uses AI, machine learning, and behavioral science to power practice solutions for inpatient, perioperative, emergency department, and command center settings. It partners with health systems including Boston Medical Center, HonorHealth, M Health Fairview, Mercy, and Saint Luke's Health System. Reported outcomes include fewer excess days, reductions in length of stay, and new cases added per operating room per month. The company is led by CEO Mudit Garg. Qventus plans to use the funding to expand its technology to additional hospitals and health systems across the United States. Qventus offers an AI/ML-driven software platform that streamlines and automates hospital workflows to improve flow, throughput and patient experience across emergency departments, perioperative areas, inpatient units, pharmacy and outpatient access. The platform acts as a “System of Action,” combining data, technology and people to enable real-time decision making and collaborative issue mitigation. Qventus provides modular capabilities for ED flow, perioperative scheduling, inpatient operations, patient safety and pharmacy operations. The company reports deployments at major U.S. health systems including NewYork-Presbyterian, Emory Healthcare and the Mercy health system, and its software has enabled more than 3.8M patient encounters to date. Qventus is based in Silicon Valley/Mountain View and plans to use new capital to continue rapid expansion of its AI-based platform across health systems. analyticsMD, based in Mountain View, CA and led by CEO Mudit Garg, provides an AI-powered hospital operations software platform. The platform collects large amounts of messy healthcare data, processes it in real time to predict issues and outcomes, and recommends immediate course-corrections that are sent to frontline teams. It addresses operational challenges across emergency departments, perioperative areas, inpatient and outpatient settings. The software is used by community, academic and public hospitals including Lucile Packard Children’s Hospital Stanford, El Camino Hospital, Sutter Auburn Faith Hospital, St. Joseph’s Medical Center, Medstar Montgomery Medical Center, Natividad Medical Center and Mercy. analyticsMD plans to use new funding for product development and to accelerate delivery of its AI platform to U.S. health systems.

Participated · Series A · Sep 2019

InsightRX provides a cloud-based clinical decision support platform that applies quantitative pharmacology and artificial intelligence to enhance therapeutic decision-making from phase I drug development through individualized patient treatment at the point of care. The platform uses patient-specific data and quantitative models to tailor dosing for complex treatments, including antibiotics, chemotherapeutic agents, and immunosuppressants. InsightRX also employs AI to help data scientists analyze clinical-trial data, support trial design, clarify dose–exposure–response relationships, and refine dosing strategies for regulatory submissions. The company positions itself to move beyond a one-size-fits-all dosing paradigm toward individualized treatment for patient subgroups and individual patients. Leadership indicates the company will use external financing to accelerate growth and advance its strategic vision to transform patient care. InsightRX offers a precision dosing platform (Nova) and an integrated clinical analytics product (Apollo) that use patient demographics, physiology, genomics, drug concentrations and biomarkers to individualize medication dosing. The software integrates with EHRs such as Epic and Cerner and is embedded in clinical workflows to present dosing recommendations and simulations to clinicians. Its two-sided marketplace serves provider customers who buy drug modules (infectious disease, chemotherapy, immunology) and pharma/biotech clients that commission companion dosing applications for clinical trials and labels. The platforms are in use at more than a hundred healthcare institutions and life‑science organizations across the US and Europe. The company plans to deepen EHR integrations (including AllScripts and EDC systems for trials), expand into additional therapeutic areas (transplant, coagulation, IBD/Crohn’s, neutropenia) and add new product modules in infectious disease and oncology. InsightRX has raised venture funding (most recently a $10M Series A) and intends to use proceeds to accelerate integrations and product expansion. InsightRX is an early-stage San Francisco company that has developed a cloud-based precision medicine and clinical analytics platform. The platform leverages mathematical models, quantitative pharmacology, patient demographics, physiological characteristics, genomic data, drug concentrations and biomarkers to individualize drug selection and dosing. Its initial work has focused on chemotherapy drugs for children and certain complex antibiotics. The company aims to give clinicians and pharmacists tools to select the right drug and dose for the right patient, reducing adverse reactions and shortening hospital stays. Investors and partners describe the technology as having the potential to transform how drugs are administered worldwide and to enable targeted gene testing and co-development of dosing modules. InsightRX recently raised an early-stage financing led by Greatpoint Ventures Innovation Fund with participation from OSF Ventures.

Participated · Equity · Feb 2016

Bloodbuy operates a cloud-based platform that connects hospitals and blood centers nationwide, using proprietary algorithms to address uneven geographic distribution of blood supply in real time and automate redistribution. The solution is deployed at integrated delivery networks (IDNs) and blood centers across the U.S. Christopher Godfrey is the founder and CEO. The company raised $3.75M to continue expanding its integrated network of hospitals and blood centers, grow its team, and add new technology offerings. In conjunction with the funding, executives from investors joined Bloodbuy’s board. Bloodbuy announced a strategic relationship with Premier to offer its technology to Premier’s membership of approximately 3,600 U.S. hospitals and 120,000 other healthcare providers.